Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...

Sulodexide is under clinical development by Alfasigma and currently in Phase III for Venous Thromboembolism. According to GlobalData, Phase III drugs for Venous Thromboembolism have a 60% phase ...

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Mediwound (MDWD – Research Report) and keeping the price target ...

Global Compression Therapy Market Projected to Reach $5.6 Billion by 2030, Driven by Innovations and Aging Population ...

Treatment is aimed at reducing the patient ... edema, skin changes, and venous ulcers (Figure 1). 1,6 Venous hypertension reduces shear stress, which maintains the endothelial activation state.

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of ... open sores known as venous ulcers. The disease can severely ...

Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients ...

The event will focus on EscharEx, an innovative biologic drug in late-stage development for chronic wound debridement, specifically targeting Venous Leg Ulcers (VLUs). The event will feature three ...

Venous Stents Industry. According to the latest industry analysis from Future Market Insights, the global venous stents ...

Addressing the rising prevalence of leg and foot problems in modern society through awareness and preventive measures for better overall well-being In olden ...